Skip to main content
. Author manuscript; available in PMC: 2019 Sep 16.
Published in final edited form as: J Natl Cancer Inst. 2015 Oct 4;108(1):djv282. doi: 10.1093/jnci/djv282

Figure 2.

Figure 2.

Incremental (A) quality-adjusted life-years (QALYs) gained and (B) medical costs averted of 4- and 9-valent vaccination strategies in the United States (discounted at 3% over 70 years). Base-case: vaccine duration = lifetime, vaccine-type efficacy = 95%, cross-protective vaccine efficacy presented in Supplementary Table 3 (available online). Predictions: mean estimate generated by the 50 best-fitting parameter sets. AGW = anogenital warts; HPV = human papillomavirus; QALY = quality-adjusted life-year; vacc = vaccination.